ABSTRACT
Methane (CH4) is an important greenhouse gas emitted by vehicles. We report results of a laboratory study of methane emissions using a standard driving cycle for 30 different cars and trucks (1995-1999 model years) from four different manufacturers. We recommend the use of an average emission factor for the U.S. on-road vehicle fleet of (g of CH/g of CO2) = (15 +/- 4) x 10(-5) and estimate that the global vehicle fleet emits 0.45 +/- 0.12 Tg of CH4 yr(-1) (0.34 +/- 0.09 Tg of C yr(-1)), which represents < 0.2% of anthropogenic CH4 emissions. This estimate includes the effects of vehicle aging, cold start, and hot running emissions. The contribution of CH4 emissions from vehicles to radiative forcing of climate change is 0.3-0.4% of that of CO2 emissions from vehicles. The environmental impact of CH4 emissions from vehicles is negligible and is likely to remain so for the foreseeable future.
Subject(s)
Air Pollutants/analysis , Methane/analysis , Vehicle Emissions/analysis , Climate , Reference ValuesABSTRACT
Critical-sized defects (CSDs) were introduced into rat calvaria to test the hypothesis that absorption of surrounding blood, marrow, and fluid from the osseous wound into a bioabsorbable polymer matrix with unique microarchitecture can induce bone formation via hematoma stabilization. Scaffolds with 90% porosity, specific surface areas of approximately 10 m2/g, and median pore sizes of 16 and 32 microm, respectively, were fabricated using an emulsion freeze-drying process. Contact radiography and radiomorphometry revealed the size of the initial defects (50 mm2) were reduced to 27 +/- 11 mm2 and 34 +/- 17 mm2 for CSDs treated with poly(D,L-lactide-co-glycolide). Histology and histomorphometry revealed scaffolds filled with significantly more de novo bone than negative controls (p < 0. 007), more osteoid than both the negative and autograft controls (p < 0.002), and small masses of mineralized tissue (< 15 mm in diameter) observed within the scaffolds. Based on these findings, we propose a change in the current paradigm regarding the microarchitecture of scaffolds for in vivo bone regeneration to include mechanisms based on hematoma stabilization.
Subject(s)
Absorbable Implants , Biomedical Engineering/methods , Bone Regeneration/physiology , Bone Substitutes , Bone and Bones/injuries , Animals , Bone and Bones/surgery , Hematoma , Lactic Acid , Microscopy, Electron, Scanning , Osteogenesis , Polyglycolic Acid , Polylactic Acid-Polyglycolic Acid Copolymer , Polymers , Rats , Rats, Sprague-Dawley , SkullABSTRACT
Drug delivery devices have received considerable interest in the field of tissue engineering due to the advent of proteins that can induce proliferation and differentiation of various cells to form specific tissues and organs, for example, bone morphogenetic protein (BMP-2) for osteogenesis. In this work the delivery of a clinically relevant bioactive factor, recombinant human rhBMP-2, was tested in vivo in a rat ectopic bone induction assay. Contact radiography and radiomorphometry showed significantly more radiopacity (1798+/-183 mm2 versus. 784+/-570 mm2 radiopaque area/g scaffold) in the BMP scaffolds than controls (p < 0.002). De novo woven bone and abundant osteoid formation were confirmed from histological sections while controls contained minimal amounts of tissue. Histomorphometry revealed significantly more bone (124+/-93 mm2 versus 7+/-12 mm2) and osteoid (72+/-43 mm2 versus 20+/-21 mm2) in the BMP implants (p < 0.001). These scaffolds demonstrated the ability to deliver viable rhBMP-2 and to induce bone formation in an ectopic site.
